Literature DB >> 2258619

Hepatitis B virus nucleocapsid/pre-S2 fusion proteins expressed in attenuated Salmonella for oral vaccination.

F Schödel1, D R Milich, H Will.   

Abstract

Hybrid HBV nucleocapsid-pre-S(2) fusion proteins were stably expressed in several aromatic-dependent attenuated Salmonella typhimurium and Salmonella dublin strains. When these live recombinant bacteria were administered i.p. to BALB/c mice they induced high titer anti-hepatitis B virus core Ag (HBc) and detectable anti-pre-S2 serum antibodies. Upon oral feeding of the recombinant salmonellae to mice, the rate of seroconversion to anti-HBc was dependent on the salmonella strain used. With the best carrier strain high titer anti-HBc antibodies and lower titer anti-pre-S2 serum IgG antibodies were observed two weeks after a single oral immunization. The Ig class and IgG subclass distribution of anti-HBc antibodies after i.p. and oral immunization is consistent with the induction of functional T cell help.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2258619

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

Review 1.  Recombinant avirulent salmonellae as oral vaccine carriers.

Authors:  F Schödel
Journal:  Infection       Date:  1992 Jan-Feb       Impact factor: 3.553

2.  Viral nanoparticles as macromolecular devices for new therapeutic and pharmaceutical approaches.

Authors:  Simone Grasso; Luca Santi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2010-07-06

3.  Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system.

Authors:  C O Tacket; S M Kelly; F Schödel; G Losonsky; J P Nataro; R Edelman; M M Levine; R Curtiss
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

4.  A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization.

Authors:  S Hopkins; J P Kraehenbuhl; F Schödel; A Potts; D Peterson; P de Grandi; D Nardelli-Haefliger
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

5.  Oral vaccination of weaned rabbits against enteropathogenic Escherichia coli-like E. coli O103 infection: use of heterologous strains harboring lipopolysaccharide or adhesin of pathogenic strains.

Authors:  A Milon; J Esslinger; R Camguilhem
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

6.  Hybrid hepatitis B virus core-pre-S proteins synthesized in avirulent Salmonella typhimurium and Salmonella typhi for oral vaccination.

Authors:  F Schödel; S M Kelly; D L Peterson; D R Milich; R Curtiss
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

7.  Immunogenicity of recombinant core particles of hepatitis B virus containing epitopes of human immunodeficiency virus 1 core antigen.

Authors:  R Ulrich; G P Borisova; E Gren; I Berzin; P Pumpen; R Eckert; V Ose; H Siakkou; E J Gren; R von Baehr
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

8.  Oral vaccination with an attenuated Salmonella typhimurium strain expressing Borrelia burgdorferi OspA prevents murine Lyme borreliosis.

Authors:  M Dunne; B K al-Ramadi; S W Barthold; R A Flavell; E Fikrig
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

Review 9.  Use of hepadnavirus core proteins as vaccine platforms.

Authors:  David C Whitacre; Byung O Lee; David R Milich
Journal:  Expert Rev Vaccines       Date:  2009-11       Impact factor: 5.217

10.  The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity.

Authors:  F Schödel; A M Moriarty; D L Peterson; J A Zheng; J L Hughes; H Will; D J Leturcq; J S McGee; D R Milich
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.